Humana Raises 2026 Adjusted EPS Guidance to at Least $9.50 After Mixed Q3
Humana Inc. raised its full-year 2026 Adjusted EPS guidance to at least $9.50 from at least $9.00 after reporting third-quarter GAAP EPS of $1.33 and an Adjusted loss per share of $0.70, according to an 8-K furnished Friday.
GAAP pretax income was $216 million versus $134 million a year earlier. Adjusted pretax results were a loss of $104 million versus income of $527 million. Year-to-date GAAP EPS was $16.84 and Adjusted EPS was $17.17. The Insurance segment’s GAAP benefit ratio was 93.7%, which Humana said was favorable to management’s guidance of slightly above 94%.
Guidance and growth metrics
Humana revised GAAP EPS guidance for 2026 to at least $15.09 from at least $6.52. The company said the Adjusted EPS outlook still anticipates a year-over-year decline because of the Star Ratings headwind for Bonus Year 2026, net of mitigation.
CenterWell Senior Primary Care grew by 146,800 patients, or 30%, year to date. Medicaid membership rose by 103,600, or 7%, largely from integrated Duals programs in Michigan, Illinois, and South Carolina. Humana also said a joint venture with BlackRock replaced prior joint ventures with Welsh, Carson, Anderson & Stowe.
CEO Jim Rechtin said the company is increasingly driving financial and operating performance ahead of its plan.
By the numbers
- Q3 GAAP EPS: $1.33
- Q3 Adjusted EPS: loss of $0.70
- FY 2026 Adjusted EPS guidance: at least $9.50
- FY 2026 GAAP EPS guidance: at least $15.09
- YTD CenterWell patient growth: 146,800, or 30%
Sources
- Humana Form 8-K with third-quarter 2026 earnings release (Exhibit 99.1), filed Nov. 6, 2026 (accession 0000049071-26-000064)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.